Skip to main content

Table 1 Baseline characteristics of the included patients

From: Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial

  Empagliflozin
(n = 52)
Placebo
(n = 53)
Age, yrs 65.4 ± 11.1 64.1 ± 9.9
Males 36 (69.2) 36 (67.9)
Systolic blood pressure, mm Hg 132.8 ± 15.2 133.0 ± 14.5
Diastolic blood pressure, mm Hg 76.4 ± 11.5 74.9 ± 9.5
Body mass index, kg/m2 26.2 ± 5.1 26. 9 ± 5.5
Hemoglobin, g/dL 14.0 ± 1.6 13.7 ± 1.5
Hematocrit, % 41.6 ± 4.6 41.3 ± 4.2
Uric acid, mg/dL 5.7 ± 1.4 5.3 ± 1.1
Diabetes duration, yrs 13.6 ± 13.2 13.0 ± 8.3
Fasting plasma glucose, mg/dL 141.4 ± 25.0 146.4 ± 34.8
Glycohemoglobin, % (mmol/mol) 7.2 ± 0.8 (55 ± 9) 7.2 ± 0.9 (55 ± 10)
eGFR, mL/min/1.73m2 67.0 ± 12.5 69.2 ± 13.9
UACR, mg/g·Cre 32.0 (8.0 to 65.0) 15.3 (7.5 to 41.5)
NT-proBNP, pg/mL 63.0 (31.0 to 180.0) 80.5 (20.0 to 122.0)
High-sensitivity troponin I, pg/mL 3.2 (2.3 to 6.3) 4.1 (2.2 to 8.1)
Past medical history
 Hypertension 41 (78.8) 36 (67.9)
 Dyslipidemia 39 (75.0) 38 (71.7)
 Heart failure 23 (44.2) 19 (35.8)
 Myocardial infarction 12 (23.1) 13 (24.5)
Treatment
 Metformin 25 (48.1) 28 (52.8)
 Thiazolidinedione 12 (23.1) 13 (24.5)
 DPP-4 inhibitor 37 (71.2) 36 (67.9)
 ACE inhibitor or ARB 31 (59.6) 38 (71.7)
 Beta-blocker 19 (36.5) 19 (35.8)
 MRA 9 (17.3) 5 (9.4)
 Diuretic 8 (15.4) 10 (18.9)
  1. Data are expressed as n (%), mean ± SD or median (interquartile)
  2. ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, DPP-4 dipeptidyl peptidase-4, eGFR estimated glomerular filtration rate, MRA mineralocorticoid receptor antagonist, NT-proBNP N-terminal pro-brain natriuretic peptide, UACR urinary albumin-creatinine ratio